Dear colleagues,
Certara is pleased to announce the release of pyDarwin, version 1.0. pyDarwin
is a machine learning solution for NONMEM model selection. This is an open
source package, released under GNU GENERAL PUBLIC LICENSE. The interface is
general, any combination of options (compartments, between subject variability,
residual variability, between occasion variability, covariates, different
absorption models, different pharmacodynamic models, different number of ODEs,
nonlinear processes etc) can be searched for the optimal combination. In
addition, user defined R or python code can be run after each NONMEM model
allowing user defined penalties, such as PPC to be included in the search
criteria. pyDarwin is an all python solution, supported on Windows, Linux and
Sun Grid engine. The source package can be downloaded from
https://github.com/certara/pyDarwin
and the documentation can be found here:
https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fcertara.github.io%2FpyDarwin%2Fhtml%2Findex.html&data=05%7C01%7Cmark.sale%40certara.com%7C31a3289a45dc487bd7cc08da7637b77b%7C7287abd30220456e98514352bae208c9%7C1%7C0%7C637952278937389398%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=Ex3%2BetN5WUFPhlmGouAB5SojE4WlEUGXJJFcc49sDM0%3D&reserved=0
Feel free to contact me with any questions.
Mark
This work was supported by FDA/NIH grant (U01FD007355) (Development of a model
selection method for population pharmacokinetics analysis by deep-learning
based reinforcement learning (RFA-FD-21-027)). Views expressed in this
announcement do not represent FDA's views or policy.
Rob Bies lab at the University at Buffalo is a collaborator on this work and a
co-investigator for this work. His laboratory has contributed sample datasets
and suggestions on the strategies for model search
Mark Sale M.D.
Vice President
Integrated Drug Development
[email protected]
Remote-Forestville CA
Office Hours 9 AM - 5 PM Eastern Time
+1 302-516-1684
www.certara.com
[Certara Logo]
Quoted reply history
From: [email protected] <[email protected]> On Behalf Of
Rebecca Baillie
Sent: Wednesday, August 10, 2022 10:14 AM
To: [email protected]
Subject: [NMusers] Webinar: Injecting Reality into The Commercial Due Diligence
Process for In-Licensing, Partnering, or Purchasing Pharmaceutical Assets in
Development.
CAUTION: This email originated from outside of Certara. Do not click links or
open attachments unless you recognize the sender and know the content is safe.
Injecting Reality into The Commercial Due Diligence Process for In-Licensing,
Partnering, or Purchasing Pharmaceutical Assets in Development.
Bill Brastow, Ph.D., CTO, Market Modeling, Rosa & Co LLC, San Carlos, CA
Wednesday, August 17, 2022, 9:00 to 10:00 am PDT
Register for free at https://www.rosaandco.com/webinars
Abstract:
When performing due diligence for in-licensing, partnering, or purchasing
pharmaceutical assets in development, pharmaceutical and biotech companies
evaluate the asset based on factors including the scientific data available,
intellectual property of the asset, clinical development plan, competitive
analysis of the commercial opportunity for the asset and a financial analysis
related to revenue projections.
Companies may attempt to complete this effort on their own or they may choose
to use outside consulting firms to assist with components of the due diligence
process.
This webinar will focus on how pharmaceutical and biotech companies can inject
reality into the commercial opportunity analysis by measuring expected
physician demand for the drug to inform revenue projections and decisions about
in-licensing, partnering, or purchasing these assets.
This message (including any attachments) may contain confidential, proprietary,
privileged and/or private information. The information is intended to be for
the use of the individual or entity designated above. If you are not the
intended recipient of this message, please notify the sender immediately, and
delete the message and any attachments. Any disclosure, reproduction,
distribution or other use of this message or any attachments by an individual
or entity other than the intended recipient is prohibited.